Abstract:Transient receptor potential canonical (TRPC) channels are Ca2+-permeable nonselective cation channels implicated in diverse physiological functions, including smooth muscle contractility and synaptic transmission. However, lack of potent selective pharmacological inhibitors for TRPC channels has limited delineation of the roles of these channels in physiological systems. Here we report the identification and characterization of ML204 as a novel, potent, and selective TRPC4 channel inhibitor. A high throughput fluorescent screen of 305,000 compounds of the Molecular Libraries Small Molecule Repository was performed for inhibitors that blocked intracellular Ca2+ rise in response to stimulation of mouse TRPC4 beta by mu-opioid receptors. ML204 inhibited TRPC4 beta-mediated intracellular Ca2+ rise with an IC50 value of 0.96 mu M and exhibited 19-fold selectivity against muscarinic receptor-coupled TRPC6 channel activation. In whole-cell patch clamp recordings, ML204 blocked TRPC4 beta currents activated through either mu-opioid receptor stimulation or intracellular dialysis of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S), suggesting a direct interaction of ML204 with TRPC4 channels rather than any interference with the signal transduction pathways. Selectivity studies showed no appreciable block by 10-20 mu M ML204 of TRPV1, TRPV3, TRPA1, and TRPM8, as well as KCNQ2 and native voltage-gated sodium, potassium, and calcium channels in mouse dorsal root ganglion neurons. In isolated guinea pig ileal myocytes, ML204 blocked muscarinic cation currents activated by bath application of carbachol or intracellular infusion of GTP gamma S, demonstrating its effectiveness on native TRPC4 currents. Therefore, ML204 represents an excellent novel tool for investigation of TRPC4 channel function and may facilitate the development of therapeutics targeted to TRPC4.

Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay

Discovery of novel modulators targeting human TRPC5: Docking-based virtual screening, molecular dynamics simulation and binding affinity predication

Identification of Novel TRPC5 Inhibitors by Pharmacophore-Based and Structure-Based Approaches

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

Identification and Optimization of 2‐aminobenzimidazole Derivatives As Novel Inhibitors of TRPC4 and TRPC5 Channels

Exploring Functional Roles of TRPV1 Intracellular Domains with Unstructured Peptide-Insertion Screening.

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Structural Basis for Human TRPC5 Channel Inhibition by Two Distinct Inhibitors.

A Precise Microfluidic Assay in Single‐Cell Profile for Screening of Transient Receptor Potential Channel Modulators

The Discovery of Novel ACA Derivatives As Specific TRPM2 Inhibitors That Reduce Ischemic Injury Both in Vitro and in Vivo.

Identification of novel selective TRPV3 antagonists based on virtual screening, molecular docking and bioassay

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

Discovery of Pyrroledione Analogs As Potent Transient Receptor Potential Canonical Channel 5 Inhibitors.

Structure-Based Discovery of a Subtype-Selective Inhibitor Targeting a Transient Receptor Potential Vanilloid Channel.

Identification of ML204, a Novel Potent Antagonist That Selectively Modulates Native TRPC4/C5 Ion Channels

Pathophysiological significance and modulation of the transient receptor potential canonical 3 ion channel

Pyrazolopyrimidines As Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels.